C
Capstan Therapeutics
Advancing cell engineering to develop therapeutics for a broad range of diseases
About Capstan Therapeutics
CapstanTX is a biotechnology startup that specializes in developing targeted lipid nanoparticles (tLNPs). These are tiny particles that can be loaded with medical payloads, such as mRNA or gene editing tools, and then delivered to specific cells in the body. This technology is designed to reprogram specific cell types, potentially treating a range of diseases at their source. The company's tLNPs can be adjusted to meet safety and efficacy standards for different diseases, and they can potentially be administered in earlier disease stages and in outpatient settings.
Read full description
The company's technology is modular, meaning it can be adapted to deliver a wide range of payloads. For example, it can deliver mRNA-encoded CARs (Chimeric Antigen Receptors) to specific immune cells, programming them to eliminate disease-causing cells. It can also deliver gene editing tools to pathogenic cells, modifying their DNA to treat genetic diseases.
CapstanTX operates in the biotechnology market, serving clients in the medical and pharmaceutical industries. The company makes money by developing and licensing its technology to these clients.
The team at CapstanTX is made up of scientific leaders from various fields, including cell and gene therapy, RNA and delivery technologies, and drug development. They are committed to pioneering new medical treatments to improve market access and scalability, and to increase the range of therapeutic options available to patients.
At a glance
- Founded
- 2021
- Headquarters
- San Diego, United States
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Latest news
Press, funding announcements and product moves mentioning Capstan Therapeutics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
OrbiMed
RA Capital Management
Novartis Venture Fund
Vida Ventures
Series A11 investors entered at this stage
- PVPfizer Ventures
Eli Lilly
Polaris Partners
Bristol-Myers Squibb
Alexandria Venture Investments
Leaps by Bayer
Sofinnova Investments
Forbion Capital Partners
Johnson & Johnson Innovation
Perceptive Advisors
Mubadala Capital
Series B and later6 investors entered at this stage
- Perceptive Advisors
- FPForbion Capital Partners
- UPUniversity of Pennsylvania
- JIJohnson & Johnson Innovation
- Mubadala Capital
- SISofinnova Investments
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
6 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Capstan Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Capstan Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.